Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

EGFR inhibitors have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Mefatinib is a novel, bioavailable, second-generation, irreversible pan-EGFR inhibitor. This phase Ib/II open-label, single-arm, multi-center study investigated the efficacy, safety, biomarker, and resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pingli, Li, Yuping, Lv, Dongqing, Yang, Lingge, Ding, Liren, Zhou, Jianya, Hong, Wei, Chen, Youfei, Zhang, Dongqing, He, Susu, Zhou, Jianying, Wang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558340/
https://www.ncbi.nlm.nih.gov/pubmed/34719670
http://dx.doi.org/10.1038/s41392-021-00773-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558340/
https://www.ncbi.nlm.nih.gov/pubmed/34719670
http://dx.doi.org/10.1038/s41392-021-00773-3

Ejemplares similares